gunagratinib   Click here for help

GtoPdb Ligand ID: 11669

Synonyms: ICP-192 | ICP192
Compound class: Synthetic organic
Comment: The chemical structure for gunagratinib was obtained from WHO Proposed list 125. It mapped to PubChem CID 138734912, and from a web search it was identified as ICP-192, which is an irreversible pan-FGFR (fibroblast growth factor receptors) inhibitor that was developed by InnoCare Pharma for antitumuor potential (especially for tumours with FGF/FGFR gene aberrations). When we generated this ligand entry in August 2021, there was no published/peer reviewed report of ICP-192's pharmacology or biological activity. Phase 1 results were reported in a meeting abstract from the 2021 annual meeting of the American Society of Clinical Oncology DOI: 10.1200/JCO.2021.39.15_suppl.4092.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 111.71
Molecular weight 423.19
XLogP 2.44
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CC(=O)N1CC[C@@H](C1)n1nc(c(c1NC)C(=O)N)C#Cc1cc(OC)cc(c1)OC
Isomeric SMILES CNc1c(c(nn1[C@H]1CCN(C1)C(=O)C=C)C#Cc1cc(cc(c1)OC)OC)C(=O)N
InChI InChI=1S/C22H25N5O4/c1-5-19(28)26-9-8-15(13-26)27-22(24-2)20(21(23)29)18(25-27)7-6-14-10-16(30-3)12-17(11-14)31-4/h5,10-12,15,24H,1,8-9,13H2,2-4H3,(H2,23,29)/t15-/m0/s1
InChI Key QFUIJOBJAQBGDH-HNNXBMFYSA-N
No information available.
Summary of Clinical Use Click here for help
ICP-192 has been advanced into clinical trials to establish its safety and potential efficacy to treat solid tumours, such as urothelial carcinoma, cholangiocarcinoma and bladder cancer. In June 2021 the FDA granted gunagratinib (ICP-192) orphan designation for the treatment of cholangiocarcinoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03758664 Clinical Study of ICP-192 in Solid Tumors Patients Phase 1/Phase 2 Interventional Beijing InnoCare Pharma Tech Co., Ltd.
NCT04492293 An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer Phase 2 Interventional Beijing InnoCare Pharma Tech Co., Ltd.
NCT04565275 A Study of ICP-192 in Patients With Advanced Solid Tumors Phase 1/Phase 2 Interventional Beijing InnoCare Pharma Tech Co., Ltd.